|1.||Ellard, Sian: 20 articles (07/2015 - 09/2003)|
|2.||Hattersley, Andrew T: 16 articles (07/2015 - 09/2003)|
|3.||Gloyn, Anna L: 16 articles (07/2015 - 09/2003)|
|4.||Matschinsky, Franz M: 15 articles (02/2013 - 04/2002)|
|5.||Hattersley, A T: 11 articles (11/2007 - 01/2000)|
|6.||Pfefferkorn, Jeffrey A: 9 articles (02/2015 - 02/2012)|
|7.||Grimsby, Joseph: 9 articles (08/2012 - 01/2006)|
|8.||Owen, Katharine R: 8 articles (12/2014 - 02/2010)|
|9.||Ellard, S: 8 articles (08/2013 - 02/2000)|
|10.||Hansen, Torben: 7 articles (08/2014 - 04/2002)|
|1.||Type 2 Diabetes Mellitus (MODY)
10/01/1992 - "The discovery that glucokinase mutations can cause MODY and was also found in ten affected members of a pedigree with type 2 diabetes in which MODY had not previously been considered indicates that diagnosis based on molecular pathology will be helpful in understanding the aetiology of type 2 diabetes."
10/01/2013 - "Our study aims were to determine the frequency of MODY mutations (HNF1A, HNF4A, glucokinase) in a diverse population of youth with diabetes and to assess how well clinical features identify youth with maturity-onset diabetes of the young (MODY). "
10/01/2013 - "Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus."
02/01/2013 - "A proof of concept study was conducted to investigate the safety and tolerability of a novel oral glucokinase activator, LY2599506, during multiple dose administration to healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). "
04/01/2010 - "The aim of this study was to determine whether or not mutations in the 3 commonest forms of MODY, hepatic nuclear factor 4α (HNF4α), HNF1α and glucokinase (GK), are a cause of diabetes in young Omanis. "
02/25/1983 - "Kinetic studies of insulinoma glucokinase also indicated similarity with liver glucokinase, i.e. "
05/01/2008 - "Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks."
11/15/1996 - "Reporter plasmids with the liver glucokinase promoter and any length of flanking sequence were minimally active in INS-1 insulinoma cells, and conversely reporters with the beta-cell-specific promoter were ineffective in primary hepatocytes. "
10/01/1992 - "Multiple elements in the upstream glucokinase promoter contribute to transcription in insulinoma cells."
07/01/1988 - "Characteristics of glucokinase of the Kirkman insulinoma."
|3.||Hypoglycemia (Reactive Hypoglycemia)
04/01/2014 - "Glucokinase activators (GKAs), such as AZD1656, are designed as antihyperglycemic agents for diabetics and can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies. "
02/01/2013 - "Selecting dosing regimens for phase 2 studies for a novel glucokinase activator LY2599506 is challenging due to the difficulty in modeling and assessing hypoglycemia risk. "
04/01/2002 - "In this study, a second case of hyperinsulinemic hypoglycemia due to activation of glucokinase is reported. "
09/01/2012 - "Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses to hypoglycemia are unknown. "
09/01/2012 - "Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males."
01/01/2015 - "A new compound heterozygosis for inactivating mutations in the glucokinase gene as cause of permanent neonatal diabetes mellitus (PNDM) in double-first cousins."
12/01/2014 - "In humans, activating GCK mutations cause familial hyperinsulinaemic hypoglycaemia (GCK-HH), leading to keen interest in the potential of small-molecule glucokinase activators (GKAs) as treatments for diabetes mellitus. "
04/01/2013 - "Glucokinase (GK) is a new target for the treatment of type II diabetes mellitus (T2DM). "
01/01/2012 - "Homozygous mutations in the glucokinase gene (GCK) result in a complete deficiency of the GCK enzyme, which leads to permanent neonatal diabetes mellitus. "
01/01/2012 - "[Glucokinase gene mutation as a causative factor of permanent neonatal diabetes mellitus]."
04/01/2012 - "These findings suggest that chronic activation of glucokinase preserves beta cell mass and delays disease in the ZDF rat, a model of insulin resistance and progressive beta cell failure."
01/01/2012 - "Exendin-4-induced increase in hepatic glucokinase activity is more pronounced in the presence of hepatic insulin resistance. "
01/01/2007 - "Mice haploinsufficient for beta cell glucokinase (Gck) were unable to increase their beta cell mass in response to insulin resistance produced by high-fat feeding. "
12/01/2003 - "Moreover, we determined whether glucokinase overexpression counteracted high-fat diet-induced insulin resistance. "
12/01/2003 - "Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance."
|4.||Facilitative Glucose Transport Proteins (Glucose Transporter)
|1.||Investigational Therapies (Experimental Therapy)
|4.||Transplantation (Transplant Recipients)